Sangamo Biosciences (SGMO) Tops Q3 EPS by 3c

Sangamo Biosciences (NASDAQ: SGMO) reported Q3 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $12.4 million versus the consensus estimate of $8.27 million.

Sangamo Biosciences sees FY2014 revenue of $45-50 million, versus the consensus of $47.57 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• DA Davidson Reiterates Buy Rating on Walmart (WMT) Ahead of Earnings